{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/lipid-modification-cvd-prevention/have-i-got-the-right-topic/","result":{"pageContext":{"chapter":{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","depth":1,"htmlHeader":"<!-- begin field 5a45e506-06f8-49bb-b548-f607320dc449 --><h1>Have I got the right topic?</h1><!-- end field 5a45e506-06f8-49bb-b548-f607320dc449 -->","summary":null,"htmlStringContent":"<!-- begin item 2e762238-0e29-4266-bb10-dd1c205c9d90 --><!-- begin field 1a1e9766-b6ca-4350-be24-acbc0155a109 --><p>From age 18 years onwards.</p><!-- end field 1a1e9766-b6ca-4350-be24-acbc0155a109 --><!-- begin field 303087a0-efbb-44eb-9ad3-0b90786b143b --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2016a</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Risk estimation and the prevention of cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">SIGN, 2017</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Statins: benefits and risks</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">MHRA, 2014</a>].</p><p>This CKS topic covers the reduction of cardiovascular risk through modification of blood lipid profile. The focus is on drug treatments to reduce total and non-high density lipoprotein cholesterol (HDL-C) levels. Non-drug interventions to modify blood lipids (for example cardioprotective diet, physical activity, and weight loss) are covered in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</p><p>This CKS topic does not cover the management of blood lipids in people who have type 2 diabetes mellitus, chronic kidney disease, or familial hypercholesterolaemia. These are covered in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/hypercholesterolaemia-familial/\">Hypercholesterolaemia - familial</a>.</p><p>There are separate CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>, <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>, <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>, <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>, <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a>.</p><p>The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.</p><!-- end field 303087a0-efbb-44eb-9ad3-0b90786b143b --><!-- end item 2e762238-0e29-4266-bb10-dd1c205c9d90 -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","lastRevised":"Last revised in October 2020","chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","fullItemName":"Management","slug":"management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}